Identification and Mechanistic Characterization of a Peptide Inhibitor of Glycogen Synthase Kinase (GSK3β) Derived from the Disrupted in Schizophrenia 1 (DISC1) Protein
Authors:
Preprint
Abstract
Glycogen Synthase Kinase 3-beta (GSK3β) is a critical regulator of several cellular pathways involved in neuroplasticity and is a potential target for neurotherapeutic development in the treatment of neuropsychiatric and neurodegenerative diseases. The majority of efforts to develop inhibitors of GSK3β have been focused on developing small molecule inhibitors that compete with ATP through direct interaction with the ATP binding site. This strategy has presented selectivity challenges due to the evolutionary conservation of this domain within the kinome. The Disrupted in Schizophrenia (DISC1) protein, has previously been shown to bind and inhibit GSK3β activity. Here, we report the characterization of a 44-mer peptide derived from human DISC1 (hDISCtide) that is sufficient to both bind and inhibit GSK3β in a non-competitive mode that is distinct from classical ATP competitive inhibitors. Based on multiple independent biochemical and biophysical assays, we propose that hDISCtide interacts at two distinct regions of GSK3β: an inhibitory region that partially overlaps with the binding site of FRATide, a well-known GSK3β binding peptide, and a specific binding region that is unique to hDISCtide. Taken together, our findings present a novel avenue for developing a peptide-based selective inhibitor of GSK3β.Keywords
All Related Versions
- Published version: ACS Chemical Neuroscience, 11 (24), 4128.
This publication has 30 references indexed in Scilit:
- Wnt/β‐catenin signaling in brain development and mental disorders: keeping TCF7L2 in mindFEBS Letters, 2019
- Recent advances in understanding the cellular roles of GSK-3F1000Research, 2017
- Glycogen Synthase Kinase 32017
- Discovery of a Highly Selective Glycogen Synthase Kinase‐3 Inhibitor (PF‐04802367) That Modulates Tau Phosphorylation in the Brain: Translation for PET NeuroimagingAngewandte Chemie International Edition, 2016
- Inhibitors of Glycogen Synthase Kinase 3 with Exquisite Kinome-Wide Selectivity and Their Functional EffectsACS Chemical Biology, 2016
- Glycogen synthase kinase-3 (GSK3): Regulation, actions, and diseasesPharmacology & Therapeutics, 2015
- Structural basis of GSK-3 inhibition by N-terminal phosphorylation and by the Wnt receptor LRP6eLife, 2014
- Disrupted in Schizophrenia 1 Regulates Neuronal Progenitor Proliferation via Modulation of GSK3β/β-Catenin SignalingCell, 2009
- Prevalence, Severity, and Comorbidity of 12-Month DSM-IV Disorders in the National Comorbidity Survey ReplicationArchives of General Psychiatry, 2005
- Structural basis for recruitment of glycogen synthase kinase 3β to the axin—APC scaffold complexThe EMBO Journal, 2003